Impact News +++ Bitmine Immersion Technologies (BMNR) Announces ETH Holdings Reach 4.535 Million Tokens, and Total Crypto... (PR Newswire) +++ BITMINE IMMERSION Aktie +3,09%

DIANTHUS Aktie

>DIANTHUS Aktienkurs

70.5 EUR +24.8% (TradegateBSX)

Ask: 70.5 EUR / 90 Stück

Bid: 68.5 EUR / 90 Stück

Tagesumsatz: 265 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

DIANTHUS Aktie über LYNX handeln

Intraday

1 Jahr

>DIANTHUS Performance

1 Woche: +19,7%

1 Monat: +37,9%

3 Monate: +48,0%

6 Monate: +148,9%

1 Jahr: +167,9%

laufendes Jahr: +58,9%

>DIANTHUS Aktie

Name:

DIANTHUS THERAPEUTICS

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US2528281080 / A3ERZ4

Symbol/ Ticker:

87E (Frankfurt) / DNTH (NASDAQ)

Kürzel:

FRA:87E, ETR:87E, 87E:GR, NASDAQ:DNTH

Index:

Webseite:

https://dianthustx.com/

Profil:

Dianthus Therapeutics Inc. is a biotechnology company focused on discovering and developing precision medicines for patients with severe autoimmune and inflammatory diseases. At the core of its missio..
>Volltext..

Marktkapitalisierung:

2425.61 Mio. EUR

Unternehmenswert:

2083.88 Mio. EUR

Umsatz:

2.65 Mio. EUR

EBITDA:

-120.41 Mio. EUR

Nettogewinn:

-108.75 Mio. EUR

Gewinn je Aktie:

-3.01 EUR

Schulden:

1.11 Mio. EUR

Liquide Mittel:

48.19 Mio. EUR

Operativer Cashflow:

-94.27 Mio. EUR

Bargeldquote:

16.88

Umsatzwachstum:

-45.57%

Gewinnwachstum:

-78.68%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

DIANTHUS

Letzte Datenerhebung:

09.03.26

>DIANTHUS Kennzahlen

Aktien/ Unternehmen:

Aktien: 43.22 Mio. St.

Frei handelbar: 83.33%

Leerverk. Aktien: 18.74%

Rückkaufquote: -11.17%

Mitarbeiter: 78

Umsatz/Mitarb.: 0.07 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 60.4%

Bewertung:

KGV: -

KGV lG: -

KUV: 555.05

KBV: 4.2

PEG-Ratio: -0.33

EV/EBITDA: -

Rentabilität:

Bruttomarge: 86.71%

Gewinnmarge: -4104.78%

Operative Marge: -4558.41%

Managementeffizenz:

Gesamtkaprendite: -27.12%

Eigenkaprendite: -28.57%

>DIANTHUS Peer Group

Gesundheit, Autoimmunerkrankungen

>DIANTHUS Chart & Kurs - NASDAQ

>DIANTHUS News

09.03.26 - 13:02	US Premarket Movers: Dianthus, Hims, Jefferies, Live Nation (Bloomberg)
	S&P 500 Index futures are down 1.1% as of 7:49 a.m. in New York as the Iran war pushes the price of oil above $100 per barrel for the first time since 2022....

09.03.26 - 12:42	Dianthus Therapeutics Earnings Review: Q4 Summary (Benzinga)
	Importance Rank: 1 read more...

09.03.26 - 12:36	Dianthus Therapeutics GAAP EPS of -$1.43 misses by $0.34, revenue of $0.28M misses by $0.17M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

09.03.26 - 12:12	Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results (GlobeNewswire EN)
	Early GO decision reached in CAPTIVATE ahead of Q2'26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A ...

09.03.26 - 12:06	Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (GlobeNewswire EN)
	Early GO decision reached ahead of Q2'26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A ...

08.03.26 - 22:03

Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (GlobeNewswire EN)

NEW YORK and WALTHAM, Mass., March 08, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced a conference call and webcast to discuss the interim responder analysis results from Part A of the Phase 3 CAPTIVATE trial of claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) scheduled for tomorrow, Monday, March 9, 2026 at 8:00 a.m. ET....

05.03.26 - 16:00	Dianthus Therapeutics, Inc. (DNTH) Stock Jumps 12.0%: Will It Continue to Soar? (Zacks)
	Dianthus Therapeutics, Inc. (DNTH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term....

03.03.26 - 22:03

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)

NEW YORK and WALTHAM, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on March 2, 2026, to three newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4)....

23.01.26 - 13:00	Dianthus Therapeutics, Inc. (DNTH) Moves 9.9% Higher: Will This Strength Last? (Zacks)
	Dianthus Therapeutics, Inc. (DNTH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term....

08.01.26 - 00:00	Dianthus CFO Sells 20,000 Shares for $903,600 After Massive Year-End Run (Fool)
	This biotech developing therapies for rare autoimmune diseases reported notable insider selling in its most recent SEC disclosure....

05.01.26 - 13:03

Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire EN)

NEW YORK and WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company's participation in the 44th Annual J.P. Morgan Healthcare conference in San Francisco. Marino Garcia, CEO of Dianthus Therapeutics, will present a corporate overview on Monday, January 12, 2026 at 3:00 pm PST / 6:00 p.m. EST and will host one-on-one meetings with investors....

23.12.25 - 12:03	Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE) (GlobeNewswire EN)
	LBL-047 (DNTH212) is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function ...

06.12.25 - 07:01	Insiderhandel: CFO & CBO verkauft Aktien von Dianthus Therapeutics im Wert von 903600 USD (Insiderkauf)
	Savitz, Ryan - Vorstand - Tag der Transaktion: 2025-12-04...

15.11.25 - 06:01	Insiderhandel: EVP, Head of R&D verkauft Aktien von Dianthus Therapeutics im Wert von 3221446 USD (Insiderkauf)
	Randhawa, Simrat - Vorstand - Tag der Transaktion: 2025-11-13...

15.11.25 - 06:01	Insiderhandel: EVP, Head of R&D verkauft Aktien von Dianthus Therapeutics im Wert von 4158442 USD (Insiderkauf)
	Randhawa, Simrat - Vorstand - Tag der Transaktion: 2025-11-14...

06.11.25 - 01:01	Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
	Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of -12.79% and -39.63%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?...

05.11.25 - 23:48	Dianthus Therapeutics GAAP EPS of -$0.97 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

05.11.25 - 22:03	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results (GlobeNewswire EN)
	Claseprubart achieved statistically significant and clinically meaningful improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL), Quantitative Myasthenia Gravis (QMG), and other efficacy measures at Week 13 in Phase 2 MaGic trial in gMG...

29.10.25 - 20:36	Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting (GlobeNewswire EN)
	Positive data from Phase 2 MaGic trial presented for claseprubart in generalized Myasthenia Gravis, including new open-label extension data further supporting potential for 300mg/2mL Q4W dosing...

16.10.25 - 17:36	Dianthus to license autoimmune disease candidate in a deal worth up $1B (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Wenn jedoch die Kraft, die die menschliche Aktivität bestimmt, nicht die Vernunft ist, bleibt der Mensch unter dem Niveau seiner eigenen Möglichkeiten. - Robert Strange McNamara

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram